logo

Engineering a recombinant chlorotoxin as cell-targeted cytotoxic nanoparticles

More info
  • ReceivedNov 26, 2018
  • AcceptedJan 3, 2019
  • PublishedJan 16, 2019

Abstract

功能性蛋白质在纳米尺度的可控寡聚化提供了通过重组DNA技术来设计和生产改良材料和药物的可能性. 氯毒素(CTX), 作为一种重组的蝎毒素, 由于其优先结合癌细胞的能力而引起人们的兴趣. 本研究将氯毒素设计并自组装为12 nm的常规纳米颗粒, 这些纳米颗粒可穿透具有和天然毒素相同受体特异性的培养细胞. 这些生物相容且可生物降解的材料, 表现出与同时作为载体和治疗剂的重组毒素相应的温和但仍然显著的细胞毒活性, 有希望成为用于细胞靶向治疗胶质瘤的药物载体. 此外, 对CTX侧区域的修改可有效影响纳米颗粒的性能, 说明基于CTX的构建体可通过常规基因工程来调节其多重功能性.


Funded by

the Agencia Estatal de Investigación(AEI)

Fondo Europeo de Desarrollo Regional(FEDER)

AGAUR(2017SGR-229)

CIBER-BBN(project,VENOM4CANCER)

ISCIII(PI15/00272,co-founding,FEDER)


Acknowledgment

This study has been funded by the Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (project VENOM4CANCER) granted to Villaverde A, ISCIII (PI15/00272 co-founding FEDER) to Vázquez E. Protein production and DLS have been partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER-BBN/IBB (http://www.nanbiosis.es/unit/u1-protein-production-platform-ppp/) and the Biomaterial Processing and Nanostructuring Unit (http://www.nanbiosis.es/portfolio/u6-biomaterial-processing-and-nanostructuring-unit/). Cytometry and cell culture experiments were performed at the Cytometry and Cell Culture Unit of the UAB (SCAC). Díaz R received an overseas predoctoral fellowship from Conacyt (Gobierno de México, 2016). Sánchez-Garcia L was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051), Serna N was supported by a predoctoral fellowship from the Government of Navarra, and Unzueta U is supported by PERIS program from the health department of la Generalitat de Cataluña. Villaverde A received an ICREA ACADEMIA award.


Interest statement

The authors declare no conflict of interest.


Contributions statement

Díaz R performed most of the protein production and characterization experiments assisted by Sánchez-Garcia L, Serna N, Cano-Garrido O and Sánchez JM. Serna N, Díaz R and Sánchez-garcía L designed the fusion proteins and Sánchez-Chardi A performed the electron microscopy studies. All authors have discussed the data and prepared the figures and methods. Unzueta U, Vazquez E and Villaverde A conceived the study, supervised the experiments and organized the figures. The manuscript was mainly written by Villaverde A.


Author information

Raquel Díaz studied chemical engineering at the University of Sonora, (Mexico, 2008) and achieved a one-year academic exchange at the University of British Columbia (Canada, 2007-2008). Later she fulfilled her Master’s study in materials science at the University of Sonora (Mexico, 2012) and is currently studying her PhD in biotechnology at the Autonomous University of Barcelona (Spain, 2019), particularly in the cancer research investigation line.


Ugutz Unzueta developed his PhD in Biotechnology at the Nanobiotechnology group led by Prof. Villaverde at the Autonomous University of Barcelona and he is currently a post-doctoral researcher at Oncogenesis and Antitumoral drugs group at Sant Pau Biomedical Research Institute in Barcelona. His research line is mainly focused on the design, production and characterization of self-assembling protein nanoparticles and nanoconjugates for targeted cancer nanomedicines.


Antonio Villaverde graduated in biological sciences in 1982 and got his PhD in 1985. Since 1987, he is Professor of Microbiology at the Universitat Autònoma de Barcelona in Spain, where he got a Full Professorship in 2002. He leads the Nanobiotechnology group in this university and in the CIBER-BBN, and he is devoted to the design of protein-based materials for biomedical applications. He founded the journal Microbial Cell Factories in 2002 being its Editor-in-Chief for 15 years.


Supplement

Supplementary information

Experimental details are available in the online version of the paper.


References

[1] Serna N, Sánchez-García L, Unzueta U, et al. Protein-based therapeutic killing for cancer therapies. Trends Biotech, 2018, 36: 318-335 CrossRef PubMed Google Scholar

[2] DeBin JA, Maggio JE, Strichartz GR. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion. Am J Physiol-Cell Physiol, 1993, 264: C361-C369 CrossRef PubMed Google Scholar

[3] DeBin JA, Strichartz GR. Chloride channel inhibition by the venom of the scorpion Leiurus quinquestriatus. Toxicon, 1991, 29: 1403-1408 CrossRef Google Scholar

[4] Veiseh M, Gabikian P, Bahrami SB, et al. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res, 2007, 67: 6882-6888 CrossRef PubMed Google Scholar

[5] Deshane J, Garner CC, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem, 2003, 278: 4135-4144 CrossRef PubMed Google Scholar

[6] Xu T, Fan Z, Li W, et al. Identification of two novel chlorotoxin derivatives CA4 and CTX-23 with chemotherapeutic and anti-angiogenic potential. Sci Rep, 2016, 6: 19799 CrossRef PubMed ADS Google Scholar

[7] Ojeda PG, Henriques ST, Pan Y, et al. Lysine to arginine mutagenesis of chlorotoxin enhances its cellular uptake. Biopolymers, 2017, 108: e23025 CrossRef PubMed Google Scholar

[8] Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliver, 2007, 4: 175-186 CrossRef PubMed Google Scholar

[9] Kasai T, Nakamura K, Vaidyanath A, et al. Chlorotoxin fused to IgG-Fc inhibits glioblastoma cell motility via receptor-mediated endocytosis. J Drug Deliver, 2012, 2012: 1-10 CrossRef PubMed Google Scholar

[10] Vazquez E, Mangues R, Villaverde A. Functional recruitment for drug delivery through protein-based nanotechnologies. Nanomedicine, 2016, 11: 1333-1336 CrossRef PubMed Google Scholar

[11] Rueda F, Céspedes MV, Conchillo-Solé O, et al. Bottom-up instructive quality control in the biofabrication of smart protein materials. Adv Mater, 2015, 27: 7816-7822 CrossRef PubMed Google Scholar

[12] Serna N, Céspedes MV, Sánchez-García L, et al. Peptide-based nanostructured materials with intrinsic proapoptotic activities in CXCR4+ solid tumors. Adv Funct Mater, 2017, 27: 1700919 CrossRef Google Scholar

[13] Sánchez-García L, Serna N, Álamo P, et al. Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs. J Control Release, 2018, 274: 81-92 CrossRef PubMed Google Scholar

[14] Díaz R, Pallarès V, Cano-Garrido O, et al. Selective CXCR4+ cancer cell targeting and potent antineoplastic effect by a nanostructured version of recombinant ricin. Small, 2018, 14: 1800665 CrossRef PubMed Google Scholar

[15] Céspedes MV, Unzueta U, Aviñó A, et al. Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO Mol Med, 2018, 10: e8772 CrossRef PubMed Google Scholar

[16] Unzueta U, Ferrer-Miralles N, Cedano J, et al. Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials, 2012, 33: 8714-8722 CrossRef PubMed Google Scholar

[17] Sánchez JM, Sánchez-García L, Pesarrodona M, et al. Conformational conversion during controlled oligomerization into nonamylogenic protein nanoparticles. Biomacromolecules, 2018, 19: 3788-3797 CrossRef PubMed Google Scholar

[18] Céspedes MV, Unzueta U, Tatkiewicz W, et al. In vivo architectonic stability of fully de novo designed protein-only nanoparticles. ACS Nano, 2014, 8: 4166-4176 CrossRef PubMed Google Scholar

[19] Unzueta U, Céspedes MV, Ferrer-Miralles N, et al. Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine, 2012, 7: 4533-4544 CrossRef PubMed Google Scholar

[20] Serna N, Céspedes MV, Saccardo P, et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. NanoMed-Nanotechnol Biol Med, 2016, 12: 1241-1251 CrossRef PubMed Google Scholar

[21] Locatelli E, Naddaka M, Uboldi C, et al. Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma. Nanomedicine, 2014, 9: 839-849 CrossRef PubMed Google Scholar

[22] Graf N, Mokhtari TE, Papayannopoulos IA, et al. Platinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cells. J Inorg Biochem, 2012, 110: 58-63 CrossRef PubMed Google Scholar

[23] Asphahani F, Wang K, Thein M, et al. Single-cell bioelectrical impedance platform for monitoring cellular response to drug treatment. Phys Biol, 2011, 8: 015006 CrossRef PubMed ADS Google Scholar

[24] Locatelli E, Broggi F, Ponti J, et al. Lipophilic silver nanoparticles and their polymeric entrapment into targeted-PEG-based micelles for the treatment of glioblastoma. Adv Healthcare Mater, 2012, 1: 342-347 CrossRef PubMed Google Scholar

[25] Poty S, Désogère P, Goze C, et al. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities. Dalton Trans, 2015, 44: 5004-5016 CrossRef PubMed Google Scholar

[26] Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. J Biol Chem, 2003, 278: 585-590 CrossRef PubMed Google Scholar

[27] Dardevet L, Rani D, Aziz TAE, et al. Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion. Toxins, 2015, 7: 1079-1101 CrossRef PubMed Google Scholar

[28] Allen M, Bjerke M, Edlund H, et al. Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med, 2016, 8: 354re3 CrossRef PubMed Google Scholar

[29] Shen J, Wolfram J, Ferrari M, et al. Taking the vehicle out of drug delivery. Mater Today, 2017, 20: 95-97 CrossRef PubMed Google Scholar

  • Figure 1

    Modular organization of CTX-based building blocks and nanoparticle characterization. (a) Schematic representation of the fusion proteins showing the amino acid sequences, where CTX (green) is placed at the amino termini and a hexahistidine tail (H6, blue) at the carboxy termini. Linker regions (purple) were placed in both cases between CTX and GFP (grey), to ensure fluorescence emission of the fusion protein. A cationic (red) region was inserted in CTX-KRKRK-GFP-H6 downstream the CTX. Siding amino acid sequences, we show the Comassie blue staining of proteins upon elution from affinity chromatography and polyacrylamide gel electrophoresis. Relevant molecular weight markers are indicated. At the bottom, the molecular weights of the whole constructs as determined by matrix-assisted laser desorption/ ionization time of flight mass spectrometry. (b) Field emission scanning electron microscopy images of purified protein, showing their nanoarchitecture. Particles were diluted in two buffers, in which nanoparticles were tested for stability, namely carbonate buffer (C) and carbonate buffer plus 333 mmol L−1 NaCl (C+S). Bar size is 20 nm in all panels. (c) Dynamic light scattering plots showing the hydrodynamic size of nanoparticles. The peak value and the polydispersion index (Pdi) are indicated. Determinations were done on the material dissolved in buffer C and C+S. (d) The hydrodynamic size of the particles in these buffers was also determined in presence of 10% BSA and in Optipro cell culture medium. SDS (at 1%), that promotes the disassembling of protein-only nanoparticles was alternatively added to the buffer to identify the size of the building blocks. The size of the parental GFP-H6 is also indicated in nm. Untreated nanoparticles are shown by coloured plots. All the experiments were performed at pH 8. The peak value of the samples in SDS, BSA and Optipro are specified over the respective plots.

  • Figure 2

    Cell penetrability of CTX-based nanoparticles. (a) Internalized nanoparticles in two alternative cell lines, namely HeLa and U87MG cells, 24 h after exposure to different protein amounts. Intracellular fluorescence was corrected by the specific emission to result in data representative of protein amounts. Cells were submitted to a harsh trypsin treatment before measurements to remove externally attached protein as described [26]. Nanoparticles were administered as dissolved in either C or C+S buffer. Y axis scales might be not precisely comparable. (b) Selective antibody-mediated inhibition of nanoparticle uptake in HeLa cells, by an anti-annexin-2 monoclonal antibody (mAb) and polyclonal antibody (pAb). The statistical analysis was performed using an ANOVA Tukey’s multiple comparisons test (*p< 0.05; **p< 0.01). Normality was confirmed by Shapiro-Wilk W where p ˃ 0.05. Comparisons were done always with samples without antibody. (c) Internalization of the related CXCR4-binding T22-GFP-H6 nanoparticles in (CXCR4+) HeLa cells, and inhibition by the CXCR4 antagonist AMD3100 at an excess molar ratio 10:1. The parental GFP-H6 protein is unable to enter cultured cells. All the experiments using HeLa cells were performed at pH 7.0–7.4, and those using U87MG cells at pH 6.8–7.2.

  • Figure 3

    Cell viability upon exposure to CTX-based nanoparticles. HeLa cells (a) and U87MG cells (b) were exposed to protein nanoparticles for 72 h. Nanoparticles were administered as dissolved in either C or C+S buffer. The statistical analysis was performed using an ANOVA Tukey’s multiple comparisons test (*p< 0.05; **p< 0.01). Normality was confirmed by Shapiro-Wilk W where p ˃ 0.05. Symbols at the top of the bars indicate the comparison with the control (100%). Symbols at the left of the bars indicate comparisons between protein pairs, indicated by white linkers. (c) HeLa cell viability upon exposure to control, non-toxic GFP-H6 protein and cytotoxic T22-PE24-H6 nanoparticles. All the experiments using HeLa cells were performed at pH 7.0–7.4, and those using U87MG cells at pH 6.8–7.2.

Copyright 2019 Science China Press Co., Ltd. 《中国科学》杂志社有限责任公司 版权所有

京ICP备18024590号-1